Coherus BioSciences (CHRS) Receives Adverse PTAB Decision Over HUMIRA IPR

November 7, 2016 12:40 PM EST

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Coherus BioSciences, Inc. (Nasdaq: CHRS) announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of Coherus’ petition for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,114,166 (the “’166 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.

“While we are disappointed by this outcome it is important to note that our longstanding strategy has been to develop and preserve multiple options pursuant to adalimumab formulation intellectual property. There are additional scientific and legal approaches available to address the various formulation intellectual property challenges, and all of the arguments raised in our IPR petition remain available in a District Court proceeding,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “Coherus remains committed to launching our HUMIRA biosimilar once approved.”

Coherus’ management team will host a conference call on Monday, November 7, 2016 at 2:30 pm ET.

Conference Call Information

Dial-in: (844) 452-6826 (domestic) or (765) 507-2587 (international) Conference ID: 13640467Please join the conference call at least 10 minutes early to register.

A replay of this conference call will be posted to the company’s website and will be available until November 30, 2016.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Conference Calls, Corporate News, Hot Corp. News, Litigation, Management Comments

Add Your Comment